BRAF inhibitors such as dabrafenib, encorafenib, and vemurafenib focus on melanoma and NSCLC with BRAF mutations [97], while Bruton tyrosine kinase inhibitors such as acalabrutinib and ibrutinib are used for mantle cell lymphoma and chronic lymphocytic leukemia, among others [98]. The gene discussed is BRAF; the disease is melanoma.